Clinical activity of ipilimumab for metastatic uveal melanoma

Abstract

Ipilimumab can induce clinical responses and durable stable disease, with manageable toxicity, in metastatic uveal melanoma. Eastern Cooperative Oncology Group performance status and pretreatment low‐density lipoprotein levels correlate with improved survival in multivariate analysis, and the week‐7 absolute lymphocyte count may represent a biomarker of treatment efficacy.